Achillion Pharmaceuticals (ACHN) gives an HCV pipeline update.
Sovaprevir is still on clinical hold even though the company says it has "addressed all issues noted in the FDA's June 29, 2013 letter." (previous)
As for the sovaprevir/ACH-3102/ribavirin combo, rapid virologic response was 79%. That doesn't appear to stack up too well with results from BMY, GILD, and ABBV if one assumes RVR is a good indicator of SVR. (more on this here)
Additionally, the company indicates it will advance ACH-2684 into Phase 2 combo studies. (PR)
ACHN -44% AH